415
Participants
Start Date
February 25, 2021
Primary Completion Date
November 1, 2023
Study Completion Date
March 31, 2028
[Lu-177]-PNT2002
Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
Abiraterone
Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
Enzalutamide
Enzalutamide (160 mg orally qd)
New York Presbyterian Hospital/Weill Cornell Medical Center, New York
La Timone Hospital, Nuclear Medicine Department, Marseille
Perelman Center for Advanced Medicine, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Maryland Greenebaum Cancer Center, Baltimore
Chesapeake Urology Associates (CUA) P.A., Towson
Carolina Urologic Research Center, Myrtle Beach
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Montpellier Cancer Institute, Department of Nuclear Medicine, Montpellier
Vanderbilt-Ingram Cancer Center, Nashville
University of Kentucky Chandler Medical Center, Lexington
Sahlgrenska University Hospital, Gothenburg
Tri-State Urologic Services, Cincinnati
Greater Dayton Cancer Center, Kettering
University of Michigan Hospitals, Ann Arbor
Karmanos Cancer Center, Detroit
University of Iowa Hospitals and Clinics, Iowa City
Claude Huriez Hospital, Lille
Center Jean Perrin, Department of Medical Oncology, Clermont-Ferrand
VA St. Louis Health Care System, St Louis
Saint Louis University Hospital, St Louis
Washington University School of Medicine, St Louis
Urology Cancer Center, PC, Omaha
Leon Berard Center, Lyon
Tulane University Medical Center, New Orleans
Tenon Hospital, Department of Medical Oncology, Paris
Dallas VA Medical Center, Nuclear Medicine Service, Dallas
UT Southwestern Medical Center, Dallas
Excel Diagnostics & Nuclear Oncology Center, Houston
University of Colorado Hospital, Aurora
Arizona Institute of Urology (AIU) - Tucson, Tucson
New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center, Albuquerque
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
VA Greater Los Angeles Healthcare System, Los Angeles
University of California Los Angeles, Nuclear Medicine Clinic, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
UC Irvine Chao Family Comprehensive Cancer Center, Orange
Stanford Cancer Institute, Palo Alto
Swedish Cancer Institute Research, Seattle
Astera Cancer Care, East Brunswick
BC Cancer - Vancouver, Vancouver
Nova Scotia Health Authority, Halifax
London Health Sciences Center - Victoria Hospital, London
Sunnybrook Research Institute, Odette Cancer Center, Toronto
Princess Margaret Cancer Centre, Toronto
CHUM - University Hospital of Montreal, Montreal
Jewish General Hospital, Montreal
CHU of Quebec - Laval University, Québec
St. Antonius Hospital, Nieuwegein
Radboud University Medical Center (Radboudumc), Nijmegen
Norrlands University Hospital, Department of Radiation Sciences, Oncology, Umeå
Charing Cross Hospital, Department of Medical Oncology, London
Royal Marsden NHS Foundation Trust - Institute of Cancer Research, Sutton
Erasmus University Medical Center Rotterdam, Rotterdam
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
INDUSTRY